Prelude Therapeutics Incorporated (PRLD)
PRLD trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1678660/000119312526099428/0001193125-26-099428-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PRLD on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2020 |
| SEC CIK | 0001678660 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $12.1M |
| Net income | -$99.5M |
| Operating income | -$104.6M |
| Net margin | -819.6% |
| Operating margin | -861.3% |
| Revenue growth | +73.4% |
| Cash | $35.3M |
| Total assets | $141.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 22.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-08-11 |
| Cash and burn | $26.3M cash; operating cash flow -$8.3M a quarter. | Report 2026-06-30 |
| Shares outstanding | 79,803,485 (2026-08-06); 56,600,345 a year earlier; 54,808,715 three years earlier. | Cover page 2026-08-06 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-04-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-24 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $12.5M, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q2 2026 2026-06-30 | $5.7M | -$13.9M | -$15.6M | $26.3M | No debt tags | $22.4M | 10-Q 2026-08-11 |
| Q1 2026 2026-03-31 | $4.6M | -$10.4M | -$21.7M | $21.8M | No debt tags | $16.7M | 10-Q 2026-05-12 |
| Q4 2025 2025-12-31 | $5.6M | -$16.5M | $23.1M | $35.3M | No debt tags | $12.1M | 10-K 2026-03-10 |
| Q3 2025 2025-09-30 | $6.5M | -$19.7M | -$19.1M | $47.5M | No debt tags | $10.5M | 10-Q 2025-11-12 |
| Q2 2025 2025-06-30 | $0 | -$31.2M | -$26.1M | $25.8M | No debt tags | $7.0M | 10-Q 2026-08-11 |
| Q1 2025 2025-03-31 | $0 | -$32.1M | -$34.2M | $40.3M | No debt tags | Needs four quarters | 10-Q 2026-05-12 |
| Q4 2024 2024-12-31 | $4.0M | -$28.7M | -$20.7M | $12.5M | No debt tags | $7.0M | 10-K 2026-03-10 |
| Q3 2024 2024-09-30 | $3.0M | -$32.3M | -$27.3M | $11.1M | No debt tags | Needs four quarters | 10-Q 2025-11-12 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-04-21 |
| Latest annual report | 10-K | 2026-03-10 |
| Latest quarterly / interim | 10-Q | 2026-08-11 |
| Latest current report | 8-K | 2026-09-10 |
| Latest proxy | DEFA14A | 2026-04-29 |
Source: SEC EDGAR submissions feed, 389 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.2% |
| 1 month | -3.1% |
| 3 months | -35.6% |
| Year to date | +19.0% |
| 1 year | +128.5% |
| From 52-week high | -48.0% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| INO | Inovio Pharmaceuticals Inc. | $1.40 | -2.10% | $262.2M |
| TTRX | Turn Therapeutics Inc. | $8.55 | -8.51% | $261.4M |
| FULC | Fulcrum Therapeutics Inc. | $3.71 | -1.59% | $283.4M |
| EVMN | Evommune Inc. | $7.10 | -6.95% | $293.6M |
| QTTB | Q32 Bio Inc. | $8.29 | -4.82% | $248.1M |
| EBS | Emergent BioSolutions Inc. | $5.81 | +0.35% | $298.7M |
| ALT | Altimmune Inc. | $1.56 | -5.17% | $303.6M |
| LFCR | Lifecore Biomedical Inc. | $6.42 | -0.08% | $243.2M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier